Clinical-scale Rapid Autologous BK-virus Specific T Cell Line generation from Kidney Transplant Recipients with Active Viremia for Adoptive ImmunotherapyInvivoscribe Marketing2021-02-12T21:23:31-08:00November 11th, 2017|2017 Publications, Publications| Read more
Invivoscribe® Releases LymphoTrack® TRB Assay on MiSeq® and LymphoTrack® Minimal Residual Disease (MRD) Softwarewmm2021-02-26T19:12:40-08:00November 7th, 2017|2017 Press Releases, Press Releases| Read more
Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance)Invivoscribe Marketing2021-02-12T00:14:15-08:00August 9th, 2017|2017 Publications, Publications| Read more
Invivoscribe® Releases LeukoStrat® CDx FLT3 Mutation Assay as CE-marked IVD Assay Kit.wmm2021-02-26T19:12:46-08:00August 1st, 2017|2017 Press Releases, Press Releases| Read more
Detection of Immunoglobulin Heavy Chain Gene Clonality by Next-Generation Sequencing for Minimal Residual Disease Monitoring in B-Lymphoblastic LeukemiaInvivoscribe Marketing2021-02-12T00:59:47-08:00July 3rd, 2017|2017 Publications, Publications| Read more
In vitro co-expression of human amyloidogenic immunoglobulin light and heavy chain proteins: a relevant cell-based model of AL amyloidosisInvivoscribe Marketing2021-02-12T01:06:38-08:00June 20th, 2017|2017 Publications, Publications| Read more
Phenotypic and functional characterization of T cells in white matter lesions of multiple sclerosis patientsInvivoscribe Marketing2021-02-12T00:57:59-08:00June 17th, 2017|2017 Publications, Publications| Read more
T and B cell clonal expansion in Ras associated lymphoproliferative disease (RALD) as revealed by next generation sequencingInvivoscribe Marketing2021-02-12T00:17:56-08:00May 30th, 2017|2017 Publications, Publications| Read more
FDA approves new combination treatment for acute myeloid leukemiawmm2021-02-26T19:12:55-08:00April 28th, 2017|2017 Press Releases, Press Releases| Read more
Invivoscribe® Receives FDA Approval for the LeukoStrat® CDx FLT3 Mutation Assay Companion Diagnostic Test for the Selection of Patients for Rydapt® and is the First Companion Diagnostic for AMLwmm2021-02-26T19:13:02-08:00April 28th, 2017|2017 Press Releases, Press Releases| Read more
Molecular pathology diagnosis of diffuse large B cell lymphoma using BIOMED-2 clonal gene rearrangementsInvivoscribe Marketing2021-02-12T01:03:26-08:00April 27th, 2017|2017 Publications, Publications| Read more
A Small Case Series of Intravascular Large B-Cell Lymphoma with Unexpected Findings: Subset of Cases with Concomitant Extravascular Central Nervous System (CNS) Involvement Mimicking Primary CNS LymphomaInvivoscribe Marketing2021-02-12T01:10:12-08:00April 17th, 2017|2017 Publications, Publications| Read more
Invivoscribe Expands Business into Solid Tumors with Assays and Services to Identify and Monitor CAR-T and TCR Immuno-Therapieswmm2021-02-26T19:13:49-08:00March 28th, 2017|2017 Press Releases, Press Releases| Read more
Invivoscribe Expands Ion PGM NGS Platform Menu: Releases Additional CE-IVD Clonality Kits with Bioinformatics Software and RUO Kits with MRD Softwarewmm2021-02-26T19:13:58-08:00February 28th, 2017|2017 Press Releases, Press Releases| Read more
Invivoscribe Announces Long-Term Collaboration Agreement with Illumina and Plans Release of NGS-based IVD Assay Kitswmm2021-02-26T19:14:04-08:00February 14th, 2017|2017 Press Releases, Press Releases| Read more
Invivoscribe Expands Long-Term Collaboration Agreement to Release FLT3 Mutation and Clonality Assay Kitswmm2021-02-26T19:14:11-08:00January 31st, 2017|2017 Press Releases, Press Releases| Read more